Cambrex up in Q3

- Last updated on GMT

Cambrex’s operating profit grew by 24 per cent year-on-year supported by higher volumes of an API using its polymeric drug delivery technology and higher controlled substances and custom development revenues.

The contract manufacturing organisation (CMO) achieved an operating income of $5.6m (€3.8m) on net sales of $57.5m, up 2.1 per cent, but expects a dip to occur in the fourth quarter.

Cambrex attributes this anticipated decline to volatility in the timing of orders and weakness in preclinical and clinical phase projects. Furthermore, price and volume pressures are squeezing Cambrex’s generic active pharmaceutical ingredient (API) business.

Related topics: Contract Manufacturing